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Assessment of distress and quality of life of cancer patients 
over the course of chemotherapy
Objective. Assess the prevalence of distress and quality of life 
of cancer patients over the course of chemotherapy. Method. 
Longitudinal prospective study addressing 200 patients. The 
Distress Thermometer (DT) and Functional Assessment of 
Chronic Illness Therapy-General (FACT-G), as indicators of 
distress and quality of life, were applied at three points in time 
during chemotherapy: the first day (T1), half way through the 
treatment (T2), and last day of medication (T3). Results. The 
average age was 56.8 years old, and 70% were women while 
the most frequent types of cancer included breast (30%) and 
hematological (22%) cancers. The number of patients with a high 
level of distress statistically decreased over time (T1=41.5%, 
T2=8.0% and T3=2.5%); consequently, quality of life scores 
improved (T1=85.6%, T2=90.4% and T3=92.0%). Patients 
with moderate to severe distress experienced worse quality of life. 
Distress, type of cancer and disease stage significantly impacted 
quality of life. Conclusion. There was a reduction in the time 
of impact from the side effects of chemotherapy in the patients 
as a consequence of adapting to the diagnosis and treatment. 
Continuous assessment of the needs of patients is essential to 
ensuring integral and humanized care, contributing to improved 
oncological nursing. 
Key words: anxiety; quality of life; health services; oncologic 
nursing; neoplasms.
Prevalencia del distrés y de la calidad de vida de los 
pacientes con cáncer a lo largo de su tratamiento con 
quimioterapia
Objetivo. Evaluar la prevalencia del distrés y de la calidad de 
vida de los pacientes con cáncer a lo largo de su tratamiento 
quimioterápico. Metodología. Estudio longitudinal prospectivo 
de 200 pacientes. Se aplicaron los instrumentos Termómetro de 
Distress (TD) y FACT-G (Functional Assessment of Chronic Illness 
Therapy-General) como indicador de la calidad de vida en tres 
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Introduction
The oncological literature acknowledges that many 
important changes occur both in the patient’s 
physical and psychosocial states with the event 
of a cancer diagnosis and during the treatment.1-3 
Considering the specificity of experiences that 
take place in such circumstances, the National 
Comprehensive Cancer Network (NCCN), in 
1999, proposed the use of the term distress to 
describe “a multifactorial unpleasant emotional 
experience of a psychological (cognitive, 
behavioral, emotional), social, and/or spiritual 
nature that may interfere with the ability to cope 
effectively with cancer, its physical symptoms and 
its treatment.”4 It is noteworthy that distress does 
not merely imply intense suffering5 – conceived as 
a natural response among those facing a severe 
disease4 – rather it comprises more severe clinical 
conditions that may lead to a psychiatric disorder.6 
It is then recommended that cancer patients be 
systematically assessed to prevent harm and 
promote well-being.4
In Canada, since 2006, distress has been included 
as the sixth vital sign to monitor cancer patients.7 
According to Ashbury, Findlay, Reynolds and 
McKerracher, patients not treated for symptom-
related distress used five times more frequently 
the healthcare units , twice as frequently for the 
emergence department, and were more frequently 
prescribed third- and fourth-line chemotherapy.8 
Numerous studies addressing quality of life in 
the field of oncology have been conducted in the 
last six decades.9-11 More specifically in regard to 
distress, some studies have already verified that 
quality of life is affected by its symptoms.6,12-14 
Lung cancer is more frequently associated with 
moderate to severe distress and low quality of 
life.15 In regard to breast cancer, fluctuation was 
observed in different phases of treatment, while 
quality of life was perceived as more positive 
before chemotherapy and distress reduced twelve 
months after treatment; no differences were 
found in terms of age and type of chemotherapy 
protocol.16 Zabora et al. compared 14 types of 
cancer, among 4,496 patients, and obtained 
the following classification of decreasing levels 
of distress: lung, brain, Hodgkin’s lymphoma, 
pancreas, lymphoma, liver, head and neck, 
adenocarcinoma, breast, leukemia, melanoma, 
colon, prostate and gynecological cancer.17
In short, evidence has been gathered from more 
than one decade that reaffirms the need to broaden 
knowledge concerning with distress and quality 
of life in order to guide care practices.6,9-11,18 
Systematic assessment in oncological nursing 
is required to ensure the delivery of integral 
and humanized care in all phases of the cancer 
Assessment of distress and quality of life of cancer patients over the course of chemotherapy
etapas del tratamiento con quimioterapia: primer día (T1), mitad del tratamiento (T2) y último día de 
medicación (T3). Resultados. Media de edad 56.8 años; 70%, mujeres; los tipos de cáncer más frecuentes 
fueron los de mama (30%) y los hematológicos (22%). Mientras la proporción de pacientes con alto nivel de 
distrés tuvo una disminución estadísticamente significativa a lo largo del tratamiento (T1=41.5%, T2=8.0% 
y T3=2.5%), la calidad de vida aumentó (T1=85.6%, T2=90.4% y T3=92.0%). Los pacientes con alto 
distrés presentaron peor calidad de vida. Se constató también que el distrés y el tipo y estadío del cáncer 
interfieren significativamente en la calidad de vida. Conclusión. Hay una reducción en el tiempo del impacto de 
los efectos colaterales de la quimioterapia en el paciente, como consecuencia de la adaptación al diagnóstico 
y al tratamiento. Es indispensable que se haga evaluación continua de las necesidades del paciente con 
el fin de asegurar su atención integral y los cuidados humanizados, contribuyendo al mejoramiento de la 
enfermería oncológica.
Palabras clave: ansiedad; calidad de vida; servicios de salud; Enfermería Oncológica; neoplasias.
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experience.16,18-20 That is, accurate understanding 
of patients enables nursing professionals to better 
assist patients to cope with the disease, adhere to 
treatment, and also optimizes human and material 
resources availables.9-16 For Costa-Requena, 
Rodríguez and Fernández-Ortega, the assessment 
of distress performed by a properly trained nurse 
during the initial phases of monitoring contributes 
to offer a high quality of cancer care.16
Thus, given the relevance of this subject, an 
investigation was performed with the general 
objective to assess distress and quality of 
life among cancer patients over the course of 
chemotherapy. 
Method
This descriptive and qualitative study was 
authorized by the Institutional Review Board of 
the College of Health, University of Brasilia. All 
the patients agreed to participate in the study 
by signing free and informed consent forms. 
The sample was composed of 200 patients who 
began their treatments in the Brasilia Cancer 
Center (CETTRO), a private and specialized 
service located in the Federal District, Brazil. 
The following instruments were applied: a) socio-
demographic questionnaire specifically developed 
to obtain data characterizing the study’s sample, 
composed of five items (age, gender, marital status, 
education, type of cancer, and disease stage); b) 
the Distress Thermometer (DT), proposed by the 
NCCN,4 adapted and validated to Portuguese,21 
assess the level of distress in a scale ranging 
from 0 (no distress) to 10 (extreme distress); 
and c) Functional Assessment of Chronic Illness 
Therapy-General (FACT-G), measure quality of life 
scores, indicated for adult patients with cancer. It 
was translated to and validated for Portuguese,22 
and contains 27 items assessing four domains 
of ‘well-being’ (physical, social/family, emotional 
and functional) on a four-point Likert scale.
The procedures for data collection were performed 
at three different points of the chemotherapy: the 
first day (T1); half way through the treatment 
(T2); and at the last day of chemotherapy infusion 
(T3). After each assessment, the results were 
discussed between the health team in order to 
identify emergency needs and specific demands 
that would require adjustments in the planned 
therapeutic regimen. Data were submitted to 
descriptive statistical analysis to characterize the 
sample in regard to socio-demographic and clinical 
variables. The Chi-square test was used to verify 
associations between distress and quality of life 
and also to determine the likelihood of occurrence 
and level of significance. ANOVA Repetitive 
Measures (ANOVA-RM) was performed among 
the independent variables (distress and quality 
of life) and socio-demographic data (age, gender, 
marital status, education, type of cancer and 
disease stage) to verify significant relationships 
among the variables. 
Results
The interval between T1, T2 and T3 was of five 
months on average. There was a sample loss of 
6.5% at T2 and of 3.8% at T3 due to death or 
change of treatment facilities. Table 1 presents 
the main socio-demographic characteristics of 
the patients in this study: an average age of 56.8 
years old, most patients were women (69.5%), 
married (63%), and had college degrees (55%). 
The following cancer types stood out from the 
clinical point of view: breast, hematological and 
gastrointestinal cancers while 59.5% of the 
participants had a late disease stage (III and IV).
In regard to the incidence of distress, 41.5% 
of the participants reported moderate to severe 
distress at T1 (DT ≥ 4). Marked and gradual 
decreases were observed in the subsequent 
phases: T2=9.1% and T3=4.4%. Table 2 
shows the incidence of distress over the course of 
assessments and also shows increase or decrease 
in the level of distress at T1, T2 and T3. Five 
patients did not experience improvement in their 
symptoms despite clinical follow-up performed by 
the health team. 
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Table 1. Socio-demographic profile of the participants (n = 200)
Characteristics
Age, average ± SD (Minimum - Maximum) 56.8±15.0 (18 - 89)
Female, n (%) 139 (69.5)
Marital Status, n (%)













































Table 2. Incidence of distress over the course of the treatment 
Situation Stage of treatment
T1 T2 T3
Moderate to severe distress remained 83 16 5
Mild distress remained 117 111 162
Level of distress increased 0 1 3
Level of distress decreased 0 59 10
Sample loss 0 13 7
Total 200 187 180
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Table 3. Descriptive values concerning the subscales of quality of life
Scales
Descriptive values 















































































When analyzing the relationship between the 
average level of distress, type of cancer and 
disease stage we verified that at T1, the patients 
with late disease stage (III and IV) experienced a 
higher average level of distress compared to those 
with a type of cancer with an early disease stage 
(I and II). It is important to note that patients 
with lung cancer presented a higher average level 
of distress when compared with the remaining 
participants. Additionally, patients with lung 
cancer with and early disease stage obtained 
an average level of distress higher than those 
with a late disease stage. At T2, patients with 
lung cancer continued to have higher averages, 
followed by patients with gynecological cancer. 
In regard to the disease stage, patients with lung 
cancer maintained the tendency indicated in the 
previous assessment phase (T1). Contrary to the 
result observed at T1, cases of gynecological, 
breast and hematological cancers with an early 
disease stage were associated at T2 with a higher 
average compared to similar cases with a late 
disease stage.
In the last assessment (T3), patients with head 
and neck cancer, followed by patients with lung 
cancer, presented an average level of distress 
higher than those with other types of cancer. 
In general, patients with an early disease stage 
reported a higher average in this assessment 
phase. It is worth mentioning that the average 
level of distress was higher among patients in 
a late disease stage of breast and gynecological 
cancers.
There was a slight increase in the average of 
quality of life over the course of the assessments: 
T1=85.6; T2=90.4; T3=92. When the domains 
“emotional well-being” and “functional well-
being” were assessed by FACT-G, a more evident 
increase was observed, as shown in Table 3.
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Table 4. Correlations among quality of life (FACT-G + subscales) and 
level of distress (DT) over the course of the assessments
Variable/Stage of assessment Correlation*
FACT-G – Distress
   T1
   T2




Physical well-being - Distress
   T1
   T2




Social/Family well-being - Distress
   T1
   T2




Emotional well-being - Distress
   T1
   T2




Functional well-being - Distress
   T1
   T2




* All the probability values were below 0.05.
The correlation between DT and FACT-G was 
inversely proportional over time (p<0.001); that 
is, the higher was the level of distress, the worse 
was the perceived quality of life scores (see Table 
4). The descriptive analysis of the data generated 
by FACT-G, based on the distress incidence 
configuration proposed in Table 2 shows that the 
average quality of life of the participants with 
moderate to severe distress was lower than for 
those with mild distress. For those experiencing 
mild distress at T1, the average was even higher 
when compared to those who had their level of 
distress reduced in the subsequent assessment, 
as shown in Table 5. 
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This correlation was statistically significant at 
T1, T2 and T3 for all the domains assessed by 
FACT-G with the exception of data found at T1 
in the subscale ‘social and family well-being’. 
For the remaining subscales at T1 and for the 
consecutive assessments, the correlations were 
significant (p<0.05): FACT-G (T1: c2=93.36, T2: 
c2=311.58 and T3: c2=278.39, ‘physical well-
being’ (T1: c2=45.02, T2: c2 =95.04, and T3: 
c2=152.76), ‘social and family well-being’ (T1: 
c2=13.37, T2: c2= 47.54 and T3: c2=106.88, 
‘emotional well-being’ (T1: c2=82.04, T2: 
c2=180.60, and T3: c2=282.35) and ‘functional 
well-being’ (T1: c2=84.87, T2: c2=256.73 and 
T3: c2=205.83).
The patients with gastrointestinal and 
genitourinary cancer in an early disease stage (I 
and II) at T1 showed a higher score of quality 
of life. Additionally, patients with the disease in 
an early disease stage reported higher scores of 
quality of life when compared to those whose 
disease was in a late disease stage. At T2, the 
averages of quality of life for early and late breast 
cancer stage were comparable. The average was 
slightly higher for patients with gastrointestinal 
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Table 5. Average qualify of life based on the configuration of incidences of distress





















Quality of life 75.4 92.8 66.7 88.6 95 76 60.8 84.7 93.9 68.3
Physical well-being 21.1 25.1 16.6 22.8 24.2 23 16.8 20.7 24.3 19.3
Social/Family well-being 23.4 23.9 22.6 24.1 24.4 24 21.6 23.7 24.5 21.7
Emotional well-being 14.8 20.1 14.7 20.5 22.1 15 13.4 20.4 22.3 14.3
Functional well-being 16.1 23.5 12.8 21.2 24.2 14 9.0 20.0 24.3 13.0
Note. *MSD: Moderate to Severe Distress (DT ≥ 4) or RMSD: Remained Moderate to Severe Distress (DT ≥ 4)
†MD: Mild Distress (DT ≤ 3) or RMD: Remained Mild Distress (DT ≤ 3)
‡RD: Reduced Distress (DT≤ 3)
§ID: Increased Distress (DT ≥ 4)
cancer and late disease stage (III and IV) as well 
for those with hematological and gynecological 
cancers. Patients with genitourinary or lung 
cancers in an early disease stage reported a 
higher quality of life scores compared to those 
with the same diagnosis in a late disease stage. 
At T3, patients with breast, hematological or 
gynecological cancers in a late disease stage 
obtained an average higher than patients in an 
early disease stage. 
The scores for quality of life were higher among 
patients who reported mild distress at T1. 
Additionally, the diagnoses more frequently 
related to a higher quality of life scores were 
breast and gynecological cancers. At T2 and T3 
the relationship between mild distress and higher 
quality of life score was maintained. The average 
quality of life for patients whose level of distress 
was reduced in these phases of assessment was 
also higher than for those whose level of distress 
was maintained or increased.
ANOVA-MR showed a violation of the assumption of 
Mauchly’s Sphericity test in the analysis performed 
for distress and socio-demographic variables (age, 
gender, marital status, education, type of cancer 
and disease stage). The Greenhouse-Geisser test 
was significant only for distress reduction over 
time (p<0.001). The analysis of quality of life 
(FACT-G and subscales) and the sample’s socio-
demographic characteristics indicated significant 
interaction in the Greenhouse-Geisser test for: 
FACT-G and education (p<0.05); FACT-G and 
type of cancer (p<0.05); ‘physical well-being’ and 
type of cancer (p<0.05); ‘physical well-being’ and 
disease stage (p<0.05); ‘emotional well-being’ 
and education (p<0.01); ‘emotional well-being’ 
and type of cancer (p<0.01); ‘functional well-
being’ and marital status (p<0.05); ‘functional 
well-being’ and education (p<0.05). Interaction 
was significant for increased of quality of life over 
time: FACT-G (p<0.001), ‘physical well-being’ 
(p<0.05), ‘emotional well-being’ and ‘functional 
well-being’’ (p<0.001).
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Discussion
The high incidence of distress at T1 was compatible 
with data reported in the literature,2-3,23 as well as the 
inversely proportional relationship between distress 
and quality of life over the three assessments.12-14 
The statistical analyses showed that patients with 
moderate to severe distress perceived their quality 
of life to be more negative when compared with 
those who reported mild distress.
Invest Educ Enferm. 2014;32(2) • 223
Lung cancer was more frequently associated with 
moderate to severe distress and low quality of life. 
These results corroborate a previous study conducted 
by Anant et al.15 When considering only the variable 
moderate to severe distress, we observed that at 
T2 and T3 were those patients diagnosed with 
gynecological, breast and hematological cancers, 
with a late disease stage. This finding partially 
converges with the study conducted by Zabora et 
al.,17 since lung cancer presented a higher incidence 
of moderate to severe distress while gynecological 
cancer the lower incidence. In the same study, 
hematological cancer occupied the third position, as 
it is also classified in this study. It was not possible 
to verify the relationship between distress, type of 
cancer and disease stage, which may reflect the 
limited access to information from their illness on 
the part of Brazilian patients as noted by Faria and 
Souhami.24
As already described in the literature, patients 
with lung and head and neck cancers in a late 
disease stage, reported low quality of life in all 
assessments.15 When performing ANOVA-MR, 
we observed that type of cancer and disease 
stage significantly impact the ‘physical well-
being’, ‘emotional well-being’ and ‘functional 
well-being’ domains. The variable education was 
positively correlated with quality of life. Significant 
interference of marital status was observed on 
‘emotional well-being’ and ‘functional well-being’ 
subscales. The longitudinal analysis showed that 
the impact experienced by patients was reduced 
as well as the coping with the chemotherapy 
side effects and psychosocial limitations imposed 
by the experience of cancer experience were 
improved. The marked and progressive reduction 
of distress level and increased quality of life 
scores can been seen as a result of the successful 
adaptation to the diagnosis and treatment.16 It is 
worth noting that, according to Akechi et al.25, if 
distress is not treated, the symptoms may intensify 
up to six months after the diagnosis, interfering 
with treatment adherence and consequently, with 
disease remission phase.
Additionally, the assessment and discussion 
routine enabled better identification of the 
difficulties faced by patients and implementation 
of preventive measures. The well-structured 
and consistent instruments encouraged 
communication among different professionals, 
who began employing similar parameters in their 
practice. Primarily, the optimization of cancer 
care contributed for improvement on Oncological 
Nursing practice. This study, however, presents 
limitations such as the sample size and its 
epidemiological representativeness; the fact that 
this research was conducted in a single oncology 
service; and the lack of follow-up in the survival 
phase, after T3. Therefore, we suggest multicenter 
studies and evaluation of the impact of different 
chemotherapy and treatments modalities 
(radiotherapy, surgery and immunotherapy). It 
is also appropriate in the future to undertake a 
detailed analysis between those different types 
of cancer. In short, the evidence obtained in this 
study reinforces the importance of continuous 
planning and assessment of care routines to 
ensure the delivery of integral and humanized 
care. We recommend systematic measures 
employing the instruments used in this study in 
order to increase the effectiveness and efficiency 
of oncology services.
References
1.  Loscalzo M, Clark KL, Holland J. Successful 
strategies for implementing biopsychosocial 
screening. Psycho-Oncol. 2011; 20(5):455-62.
2.  Fallowfield L, Ratcliffe D, Jenkins V, Saul J. 
Psychiatric morbidity and its recognition by 
doctors in patients with cancer. Br J Cancer. 
2011; 84(8)1011-15.
3.  Jacobsen PB, Wagner LI. A new quality standard: 
the integration of psychosocial care into routine 
cancer care. J Clin Oncol. 2012; 30:1154-59.
4.  National Comprehensive Cancer Network. Distress 
management. Clinical practice guidelines. J Natl 
Compr Canc Netw. 2003; 1(3):344-74.
5. Block SD. Assessing and managing 
depression in the terminally ill patient. 
ACP-ASIM End-of-life care consensus panel. 
American College of Physicians - American 
Assessment of distress and quality of life of cancer patients over the course of chemotherapy
224 • Invest Educ Enferm. 2014;32(2)    
Society of Internal Medicine. Ann Intern 
Med. 2000; 132(3):209-18. 
6.  Grassi L, Indelli M, Marzola M, Maestri A, Santini 
A, Piva E, et al. Depressive symptoms and quality 
of life in home-care-assisted cancer patients. J 
Pain Symptom Manage. 1996; 12(5):300-7.
7.  Bultz BD, Groff SL, Fitch M, Blais MC, Howes J, 
Levy K, et al. Implementing screening for distress, 
the 6th vital sign: a Canadian strategy for changing 
practice. Psycho-Oncol. 2011; 20(5):463-9.
8.  Ashbury FD, Findlay H, Reynolds B, McKerracher 
K. A Canadian survey of cancer patients’ 
experiences: are their needs being met? J Pain 
Symptom Manage. 1998; 16:298-306.
9.  Gotay CC. Quality-of-life assessment in cancer. 
In: Miller SM, Bowen DJ, Croyle RT, Rowland JH 
(Eds.). Handbook of cancer control and behavioral 
science: a resource for researchers, practitioners, 
and policymaker. Washington, DC: American 
Psychological Association; 2009. p.115-28.
10.  Faller H, Schuler M, Richard M, Heckl U, Weis J, 
Küffner R. Effects of psycho-oncologic intervention 
on emotional distress and quality of life in adult 
patients with cancer: systematic review and meta-
analysis. J Clin Oncol. 2013; 31(6):782-93.
11.  Costa Neto SB, Araujo TCCF. Qualidade de vida do 
enfermo oncológico: um panorama sobre o campo 
e suas formas de avaliação. In Carvalho VA, Franco 
MHP, Kovács MJ, Liberato RP, Macieira RC, Veit 
MT, et al (Eds.). Temas em Psico-Oncologia. São 
Paulo, SP: Summus; 2008. p.195-208.
12.  Bultz BD, Johansen C. Screening for distress, the 
6th vital sign: where are we, and where are we 
going? Psycho-Oncol. 2011; 20(6):569-71. 
13.  Andritsch E, Dietmaier G, Hofmann G, Zloklikovits 
S, Samonigg H. Global quality of life and its 
potential predictors in breast cancer patients: and 
exploratory study. Support Care Cancer. 2007; 
15:21-30.
14.  Dapueto JJ, Servente L, Francolino C, Hahn EA. 
Determinants of quality of life in patients with 
cancer. Cancer. 2005; 103:1072-81.
15.  Anant M, Randeep G, Ashutosh PJ, Manisha B, 
Hemraj P, Charu M, et al. Quality of life measures 
in lung cancer. Indian J Cancer. 2005; 42(3):125-32.
16. Costa-Requena G, Rodríguez A, Fernández-
Ortega P. Longitudinal assessment of distress and 
quality of life in the early stages of breast cancer 
treatment. Scand J Caring Sci. 2013; 27:77-83.
17.  Zabora J, Brintzenhofeszoc K, Curbow B, Hooker 
C, Piantadosi S. The prevalence of psychological 
distress by cancer site. Psycho-Oncol. 2001; 
10:19-28.
18.  Costa Neto SB, Araujo TCCF. Calidad de vida de 
los portadores de neoplasia de cabeza y de cuello 
en fase diagnóstica. Rev Colomb Psicol. 2005; 
14:53-63.
19.  Manrique FMC, Pedraza HMP. Prevalence of nursing 
diagnosis in people with oncology treatment. Invest 
Educ Enferm. 2008; 26(2):212-7.
20.  Porto AR, Thofehrn MB, Amestoy SC, Gonzáles 
RIC, Oliveira NA. The essence of interdisciplinary 
practice in palliative care delivery to cancer 
patients. Invest Educ Enferm. 2012; 30(2):231-9.
21.  Decat CS, Laros JA, Araujo TCCF. Termômetro de 
distress: validação de um instrumento breve para 
avaliação diagnóstica de pacientes oncológicos. 
Psico-USF. 2009; 14(3):253-60.
22.  Arnold BJ, Eremenco E, Chang CH, Odom L, 
Ribaudo JM, Cella DF. Development of a single 
portuguese language version of the functional 
assessment of cancer therapy general (FACIT-G) 
scale. Qual Life Res. 2000; 9(3):316.
23.  Carlson LE, Waller A, Mitchell AJ. Screening for 
distress an unmet needs in patients with cancer: 
review and recommendations. J Clin Oncol. 
2012; 30:1160-77.
24.  Faria SL, Souhami L. Communication with the 
cancer patient. Information and truth in Brazil. 
Ann N Y Acad Sci. 1997; 809(1):163-71.
25.  Akechi T, Okuyama T, Akizuki N, Azuma H, Sagawa 
R, Furukawa TA, et al. Course of psychological 
distress and its predictors in advanced non-small 
cell lung cancer patients. Psycho-Oncol. 2006; 
15:463-73.
Cristiane Decat Bergerot • Tereza Cristina Cavalcanti Ferreira de Araujo
